Biogen C.E.O. to Step Down Following Launch of Alzheimer’s Drug, Aduhelm

Biogen said on Tuesday that it will replace its chief executive and effectively give up on marketing a high-profile Alzheimer’s drug that has been a commercial failure since its controversial…

Alzheimer’s Drug Aduhelm Faces Crucial Medicare Decision

Posts supporting coverage include comments from people who have consulted for Biogen, like Dr. Jeffrey Cummings, a research professor in the department of brain health at the University of Nevada…